Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study. View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-04-11

AUTHORS

Whitney P Kirschbrown, Matts Kågedal, Bei Wang, Lars Lindbom, Adam Knott, Rachelle Mack, Sharareh Monemi, Ihsan Nijem, Sandhya Girish, Christie Freeman, Debora Fumagalli, Robin McConnell, Guy Jerusalem, Chris Twelves, José Baselga, Gunter von Minckwitz, José Bines, Amit Garg

ABSTRACT

PURPOSE: To characterize the pharmacokinetics (PK) of, and perform an exploratory exposure-response (E-R) analysis for, pertuzumab in patients with HER2-positive early breast cancer (EBC) within the APHINITY study (NCT01358877, BIG 4-11/BO25126/TOC4939G). METHODS: A previously developed pertuzumab two-compartment linear population pharmacokinetic (popPK) model was subjected to external validation to examine appropriateness for describing pertuzumab concentrations from the APHINITY study. Pharmacokinetic drug-drug interactions (DDIs) between pertuzumab, trastuzumab, and chemotherapy were assessed by comparing observed serum or plasma Cmax, Cmin, and AUClast geometric mean ratios with 90% CIs. Predictions of pertuzumab Cmax,ss, Cmin,ss, and AUCss were derived from individual parameter estimates and used in an exploratory E-R analysis. RESULTS: Using data from 72 patients, based on goodness-of-fit, the popPK model was deemed appropriate for predictions of individual exposures for subsequent comparisons to historical data, assessment of DDIs, and E-R analyses. No evidence of DDIs for pertuzumab on trastuzumab, trastuzumab on pertuzumab, or pertuzumab on chemotherapy PK was observed. Analyses of differences in exposure between patients with and without invasive disease-free survival events did not indicate improved efficacy with increased exposure. Overall Grade ≥ 3 diarrhea prevalence was higher with pertuzumab versus placebo, but was not greater with increasing pertuzumab exposure. No apparent E-R relationship was suggested with respect to other grade ≥ 3 AEs. CONCLUSION: Overall, the limited available data from this exploratory study suggest that no dose adjustments are needed for pertuzumab when administered in combination with trastuzumab and an EBC chemotherapy regimen. More... »

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-019-03826-1

DOI

http://dx.doi.org/10.1007/s00280-019-03826-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113378441

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30976844


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kirschbrown", 
        "givenName": "Whitney P", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "K\u00e5gedal", 
        "givenName": "Matts", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Bei", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "qPharmetra, H\u00e4lsov\u00e4gen 7, 141 57, Huddinge, Sweden."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lindbom", 
        "givenName": "Lars", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.419227.b", 
          "name": [
            "Roche Products Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Knott", 
        "givenName": "Adam", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.419227.b", 
          "name": [
            "Roche Products Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mack", 
        "givenName": "Rachelle", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Monemi", 
        "givenName": "Sharareh", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nijem", 
        "givenName": "Ihsan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Girish", 
        "givenName": "Sandhya", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Jules Bordet", 
          "id": "https://www.grid.ac/institutes/grid.418119.4", 
          "name": [
            "Breast European Adjuvant Study Team (BrEAST) Data Center, Institut Jules Bordet, Boulevard de Waterloo 121 (7th Floor), 1000, Brussels, Belgium."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Freeman", 
        "givenName": "Christie", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Breast International Group", 
          "id": "https://www.grid.ac/institutes/grid.427828.3", 
          "name": [
            "Breast International Group, Boulevard de Waterloo 76, 1000, Brussels, Belgium."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fumagalli", 
        "givenName": "Debora", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Frontier Science (Scotland), Grampian View, Kincraig, Inverness-Shire, PH21 1NA, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "McConnell", 
        "givenName": "Robin", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Li\u00e8ge", 
          "id": "https://www.grid.ac/institutes/grid.4861.b", 
          "name": [
            "International Breast Cancer Study Group, CHU Li\u00e8ge and Li\u00e8ge University, Domaine Universitaire du Sart Tilman, B35, 4000, Li\u00e8ge, Belgium."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jerusalem", 
        "givenName": "Guy", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "St James's University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.443984.6", 
          "name": [
            "University of Leeds and Leeds Teaching Hospitals Trust, St James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Twelves", 
        "givenName": "Chris", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "Executive Vice-President Research & Development Oncology, AstraZeneca, 950 Wind River Ln, Gaithersburg, MD, 20878, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baselga", 
        "givenName": "Jos\u00e9", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "German Breast group", 
          "id": "https://www.grid.ac/institutes/grid.434440.3", 
          "name": [
            "German Breast Group, GBG Forschungs, Martin-Behaim-Str. 12, 63263, Neu-Isenburg, Germany."
          ], 
          "type": "Organization"
        }, 
        "familyName": "von Minckwitz", 
        "givenName": "Gunter", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Instituto Nacional do C\u00e2ncer", 
          "id": "https://www.grid.ac/institutes/grid.419166.d", 
          "name": [
            "Instituto Nacional de C\u00e2ncer, Pra\u00e7a Cruz Vermelha, 23-Centro, Rio de Janeiro, 20230-130, Brazil."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bines", 
        "givenName": "Jos\u00e9", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA. garg.amit@gene.com."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garg", 
        "givenName": "Amit", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00280-014-2560-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004783955", 
          "https://doi.org/10.1007/s00280-014-2560-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(11)70336-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006777850"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1535-6108(02)00097-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009224253"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1535-6108(02)00097-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009224253"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-015-2922-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011349790", 
          "https://doi.org/10.1007/s00280-015-2922-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-015-2922-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011349790", 
          "https://doi.org/10.1007/s00280-015-2922-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1113216", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013126608"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1196/annals.1430.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018747152"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cad.0000000000000016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030996000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cad.0000000000000016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030996000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11531280-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033453107", 
          "https://doi.org/10.2165/11531280-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11531280-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033453107", 
          "https://doi.org/10.2165/11531280-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc2656", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035598015", 
          "https://doi.org/10.1038/nrc2656"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc2656", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035598015", 
          "https://doi.org/10.1038/nrc2656"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00262-005-0058-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038243318", 
          "https://doi.org/10.1007/s00262-005-0058-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00262-005-0058-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038243318", 
          "https://doi.org/10.1007/s00262-005-0058-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-016-3218-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044012265", 
          "https://doi.org/10.1007/s00280-016-3218-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-016-3218-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044012265", 
          "https://doi.org/10.1007/s00280-016-3218-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-199121040-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047951045", 
          "https://doi.org/10.2165/00003088-199121040-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdt182", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049729330"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-199427040-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053348338", 
          "https://doi.org/10.2165/00003088-199427040-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-199427040-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053348338", 
          "https://doi.org/10.2165/00003088-199427040-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35052073", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053565592", 
          "https://doi.org/10.1038/35052073"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35052073", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053565592", 
          "https://doi.org/10.1038/35052073"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35052073", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053565592", 
          "https://doi.org/10.1038/35052073"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-08-4597", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053676255"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2174/138920012802138688", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069176119"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1703643", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085866538"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4155/bio-2018-0196", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107648936"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04-11", 
    "datePublishedReg": "2019-04-11", 
    "description": "PURPOSE: To characterize the pharmacokinetics (PK) of, and perform an exploratory exposure-response (E-R) analysis for, pertuzumab in patients with HER2-positive early breast cancer (EBC) within the APHINITY study (NCT01358877, BIG 4-11/BO25126/TOC4939G).\nMETHODS: A previously developed pertuzumab two-compartment linear population pharmacokinetic (popPK) model was subjected to external validation to examine appropriateness for describing pertuzumab concentrations from the APHINITY study. Pharmacokinetic drug-drug interactions (DDIs) between pertuzumab, trastuzumab, and chemotherapy were assessed by comparing observed serum or plasma Cmax, Cmin, and AUClast geometric mean ratios with 90% CIs. Predictions of pertuzumab Cmax,ss, Cmin,ss, and AUCss were derived from individual parameter estimates and used in an exploratory E-R analysis.\nRESULTS: Using data from 72 patients, based on goodness-of-fit, the popPK model was deemed appropriate for predictions of individual exposures for subsequent comparisons to historical data, assessment of DDIs, and E-R analyses. No evidence of DDIs for pertuzumab on trastuzumab, trastuzumab on pertuzumab, or pertuzumab on chemotherapy PK was observed. Analyses of differences in exposure between patients with and without invasive disease-free survival events did not indicate improved efficacy with increased exposure. Overall Grade\u2009\u2265\u20093 diarrhea prevalence was higher with pertuzumab versus placebo, but was not greater with increasing pertuzumab exposure. No apparent E-R relationship was suggested with respect to other grade\u2009\u2265\u20093 AEs.\nCONCLUSION: Overall, the limited available data from this exploratory study suggest that no dose adjustments are needed for pertuzumab when administered in combination with trastuzumab and an EBC chemotherapy regimen.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-019-03826-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }
    ], 
    "name": "Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-019-03826-1"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113378441"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30976844"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-019-03826-1", 
      "https://app.dimensions.ai/details/publication/pub.1113378441"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-16T06:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000377_0000000377/records_106834_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s00280-019-03826-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03826-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03826-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03826-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03826-1'


 

This table displays all metadata directly associated to this object as RDF triples.

254 TRIPLES      20 PREDICATES      43 URIs      16 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-019-03826-1 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Nb26fc86bfe5048e4bbe35574bcdd25d2
4 schema:citation sg:pub.10.1007/s00262-005-0058-x
5 sg:pub.10.1007/s00280-014-2560-3
6 sg:pub.10.1007/s00280-015-2922-5
7 sg:pub.10.1007/s00280-016-3218-0
8 sg:pub.10.1038/35052073
9 sg:pub.10.1038/nrc2656
10 sg:pub.10.2165/00003088-199121040-00002
11 sg:pub.10.2165/00003088-199427040-00002
12 sg:pub.10.2165/11531280-000000000-00000
13 https://doi.org/10.1016/s1470-2045(11)70336-9
14 https://doi.org/10.1016/s1535-6108(02)00097-1
15 https://doi.org/10.1056/nejmoa1113216
16 https://doi.org/10.1056/nejmoa1703643
17 https://doi.org/10.1093/annonc/mdt182
18 https://doi.org/10.1097/cad.0000000000000016
19 https://doi.org/10.1158/0008-5472.can-08-4597
20 https://doi.org/10.1196/annals.1430.003
21 https://doi.org/10.2174/138920012802138688
22 https://doi.org/10.4155/bio-2018-0196
23 schema:datePublished 2019-04-11
24 schema:datePublishedReg 2019-04-11
25 schema:description PURPOSE: To characterize the pharmacokinetics (PK) of, and perform an exploratory exposure-response (E-R) analysis for, pertuzumab in patients with HER2-positive early breast cancer (EBC) within the APHINITY study (NCT01358877, BIG 4-11/BO25126/TOC4939G). METHODS: A previously developed pertuzumab two-compartment linear population pharmacokinetic (popPK) model was subjected to external validation to examine appropriateness for describing pertuzumab concentrations from the APHINITY study. Pharmacokinetic drug-drug interactions (DDIs) between pertuzumab, trastuzumab, and chemotherapy were assessed by comparing observed serum or plasma Cmax, Cmin, and AUClast geometric mean ratios with 90% CIs. Predictions of pertuzumab Cmax,ss, Cmin,ss, and AUCss were derived from individual parameter estimates and used in an exploratory E-R analysis. RESULTS: Using data from 72 patients, based on goodness-of-fit, the popPK model was deemed appropriate for predictions of individual exposures for subsequent comparisons to historical data, assessment of DDIs, and E-R analyses. No evidence of DDIs for pertuzumab on trastuzumab, trastuzumab on pertuzumab, or pertuzumab on chemotherapy PK was observed. Analyses of differences in exposure between patients with and without invasive disease-free survival events did not indicate improved efficacy with increased exposure. Overall Grade ≥ 3 diarrhea prevalence was higher with pertuzumab versus placebo, but was not greater with increasing pertuzumab exposure. No apparent E-R relationship was suggested with respect to other grade ≥ 3 AEs. CONCLUSION: Overall, the limited available data from this exploratory study suggest that no dose adjustments are needed for pertuzumab when administered in combination with trastuzumab and an EBC chemotherapy regimen.
26 schema:genre research_article
27 schema:inLanguage en
28 schema:isAccessibleForFree false
29 schema:isPartOf sg:journal.1088364
30 schema:name Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.
31 schema:productId N1a594ee10f2446059825f854a9516e7e
32 N5e7b87c6107a46348648c86661515fef
33 Ne23082235d154d3fa87b558fa8027e08
34 Ne6a8aa0402754c87b30455b12eb69b8c
35 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113378441
36 https://doi.org/10.1007/s00280-019-03826-1
37 schema:sdDatePublished 2019-04-16T06:25
38 schema:sdLicense https://scigraph.springernature.com/explorer/license/
39 schema:sdPublisher N2d477cd087824fe0a4c82a991d747d48
40 schema:url http://link.springer.com/10.1007/s00280-019-03826-1
41 sgo:license sg:explorer/license/
42 sgo:sdDataset articles
43 rdf:type schema:ScholarlyArticle
44 N077dcc7fb0d54efa985f67db9bf74984 rdf:first Nb71a9859b16f4135b5bc3c7003847172
45 rdf:rest N6bd0fdfec91c47038e8a38e1c268e69b
46 N0ef6fdc0d5594857a0d6bbeed75b2a44 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
47 schema:familyName Nijem
48 schema:givenName Ihsan
49 rdf:type schema:Person
50 N1065e97a05934b7b979ebd2374cd5cf1 schema:name qPharmetra, Hälsovägen 7, 141 57, Huddinge, Sweden.
51 rdf:type schema:Organization
52 N1916e670a946409d83bb2ff33d4ef8a5 schema:affiliation N1065e97a05934b7b979ebd2374cd5cf1
53 schema:familyName Lindbom
54 schema:givenName Lars
55 rdf:type schema:Person
56 N1a594ee10f2446059825f854a9516e7e schema:name nlm_unique_id
57 schema:value 7806519
58 rdf:type schema:PropertyValue
59 N20d6a580e21e4b0ea8b95d8b9dd0920a rdf:first N378696b4b3784e519dd33c8d2d0b6ed4
60 rdf:rest N8d029c143e0e47ec8a2f4369c26460ca
61 N260a800645ee4830a1162419021f2312 schema:affiliation Nb5f7ecfc2320497bbf1b6522be5f27bf
62 schema:familyName McConnell
63 schema:givenName Robin
64 rdf:type schema:Person
65 N2d477cd087824fe0a4c82a991d747d48 schema:name Springer Nature - SN SciGraph project
66 rdf:type schema:Organization
67 N3389d3a80ae64586ba2b4ea3acc4994f rdf:first Nbe4a226e7da4440380bc59ff2d317f56
68 rdf:rest N3ddb5503bee64ac899d385386613404c
69 N33acf8edd51f4807b8c54ce8f73619c5 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
70 schema:familyName Baselga
71 schema:givenName José
72 rdf:type schema:Person
73 N368ebdec862c459587f28e132935941b schema:affiliation https://www.grid.ac/institutes/grid.418119.4
74 schema:familyName Freeman
75 schema:givenName Christie
76 rdf:type schema:Person
77 N378696b4b3784e519dd33c8d2d0b6ed4 schema:affiliation https://www.grid.ac/institutes/grid.443984.6
78 schema:familyName Twelves
79 schema:givenName Chris
80 rdf:type schema:Person
81 N3ddb5503bee64ac899d385386613404c rdf:first Nad9a654088ea46f0a777c5005ebcf505
82 rdf:rest N9069ed1f99e04b4187102510184e8bd4
83 N4b3546691a6f4248a089bb973f981165 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
84 schema:familyName Wang
85 schema:givenName Bei
86 rdf:type schema:Person
87 N5e7b87c6107a46348648c86661515fef schema:name doi
88 schema:value 10.1007/s00280-019-03826-1
89 rdf:type schema:PropertyValue
90 N6bd0fdfec91c47038e8a38e1c268e69b rdf:first N368ebdec862c459587f28e132935941b
91 rdf:rest Nc73fe15eabb34b63b8204fc5d5d70268
92 N6bf6a96995ba4207b950c6dcdd85a162 rdf:first N779e27219f34468d82e7a43f213f35c0
93 rdf:rest Ncae4377fe25b463f8196b81c2bf0c336
94 N6f4906b7d0ac401683bffa332565966f rdf:first N0ef6fdc0d5594857a0d6bbeed75b2a44
95 rdf:rest N077dcc7fb0d54efa985f67db9bf74984
96 N779e27219f34468d82e7a43f213f35c0 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
97 schema:familyName Kågedal
98 schema:givenName Matts
99 rdf:type schema:Person
100 N78651eb90b7e42fd8c240b8523ccb48f schema:affiliation https://www.grid.ac/institutes/grid.4861.b
101 schema:familyName Jerusalem
102 schema:givenName Guy
103 rdf:type schema:Person
104 N7ad9a992dce44c2a9c5cc815202c934e rdf:first Nffc84079ca6a485e8f730a40eae0d3b9
105 rdf:rest Nf308e157f09a4e188da56f8b0e582e55
106 N7bc76a6f79304d55a95217fce93061a5 schema:affiliation https://www.grid.ac/institutes/grid.419227.b
107 schema:familyName Mack
108 schema:givenName Rachelle
109 rdf:type schema:Person
110 N7d502b60ee7442d9be3aff0234b4e752 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
111 schema:familyName Garg
112 schema:givenName Amit
113 rdf:type schema:Person
114 N7ff2c37dd47f4d8b97c45ddfac07372b rdf:first N1916e670a946409d83bb2ff33d4ef8a5
115 rdf:rest N7ad9a992dce44c2a9c5cc815202c934e
116 N87a166df147f490995d9f8cee9c6d496 rdf:first N78651eb90b7e42fd8c240b8523ccb48f
117 rdf:rest N20d6a580e21e4b0ea8b95d8b9dd0920a
118 N8d029c143e0e47ec8a2f4369c26460ca rdf:first N33acf8edd51f4807b8c54ce8f73619c5
119 rdf:rest N3389d3a80ae64586ba2b4ea3acc4994f
120 N9069ed1f99e04b4187102510184e8bd4 rdf:first N7d502b60ee7442d9be3aff0234b4e752
121 rdf:rest rdf:nil
122 N9133f23289c74b25b3ea1341b5766c16 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
123 schema:familyName Monemi
124 schema:givenName Sharareh
125 rdf:type schema:Person
126 N99903ab465854b86b0b73f99f2c5cebe schema:affiliation https://www.grid.ac/institutes/grid.418158.1
127 schema:familyName Kirschbrown
128 schema:givenName Whitney P
129 rdf:type schema:Person
130 Nad9a654088ea46f0a777c5005ebcf505 schema:affiliation https://www.grid.ac/institutes/grid.419166.d
131 schema:familyName Bines
132 schema:givenName José
133 rdf:type schema:Person
134 Nb26fc86bfe5048e4bbe35574bcdd25d2 rdf:first N99903ab465854b86b0b73f99f2c5cebe
135 rdf:rest N6bf6a96995ba4207b950c6dcdd85a162
136 Nb5f7ecfc2320497bbf1b6522be5f27bf schema:name Frontier Science (Scotland), Grampian View, Kincraig, Inverness-Shire, PH21 1NA, UK.
137 rdf:type schema:Organization
138 Nb6daa812de9443af932821e1822f0168 rdf:first N260a800645ee4830a1162419021f2312
139 rdf:rest N87a166df147f490995d9f8cee9c6d496
140 Nb71a9859b16f4135b5bc3c7003847172 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
141 schema:familyName Girish
142 schema:givenName Sandhya
143 rdf:type schema:Person
144 Nbe4a226e7da4440380bc59ff2d317f56 schema:affiliation https://www.grid.ac/institutes/grid.434440.3
145 schema:familyName von Minckwitz
146 schema:givenName Gunter
147 rdf:type schema:Person
148 Nc5c8a423c4e049f59f6a119459def37f rdf:first N9133f23289c74b25b3ea1341b5766c16
149 rdf:rest N6f4906b7d0ac401683bffa332565966f
150 Nc73fe15eabb34b63b8204fc5d5d70268 rdf:first Nd1c375e6abee404994d03248509f8a14
151 rdf:rest Nb6daa812de9443af932821e1822f0168
152 Ncae4377fe25b463f8196b81c2bf0c336 rdf:first N4b3546691a6f4248a089bb973f981165
153 rdf:rest N7ff2c37dd47f4d8b97c45ddfac07372b
154 Nd1c375e6abee404994d03248509f8a14 schema:affiliation https://www.grid.ac/institutes/grid.427828.3
155 schema:familyName Fumagalli
156 schema:givenName Debora
157 rdf:type schema:Person
158 Ne23082235d154d3fa87b558fa8027e08 schema:name dimensions_id
159 schema:value pub.1113378441
160 rdf:type schema:PropertyValue
161 Ne6a8aa0402754c87b30455b12eb69b8c schema:name pubmed_id
162 schema:value 30976844
163 rdf:type schema:PropertyValue
164 Nf308e157f09a4e188da56f8b0e582e55 rdf:first N7bc76a6f79304d55a95217fce93061a5
165 rdf:rest Nc5c8a423c4e049f59f6a119459def37f
166 Nffc84079ca6a485e8f730a40eae0d3b9 schema:affiliation https://www.grid.ac/institutes/grid.419227.b
167 schema:familyName Knott
168 schema:givenName Adam
169 rdf:type schema:Person
170 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
171 schema:name Medical and Health Sciences
172 rdf:type schema:DefinedTerm
173 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
174 schema:name Oncology and Carcinogenesis
175 rdf:type schema:DefinedTerm
176 sg:journal.1088364 schema:issn 0344-5704
177 1432-0843
178 schema:name Cancer Chemotherapy and Pharmacology
179 rdf:type schema:Periodical
180 sg:pub.10.1007/s00262-005-0058-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1038243318
181 https://doi.org/10.1007/s00262-005-0058-x
182 rdf:type schema:CreativeWork
183 sg:pub.10.1007/s00280-014-2560-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004783955
184 https://doi.org/10.1007/s00280-014-2560-3
185 rdf:type schema:CreativeWork
186 sg:pub.10.1007/s00280-015-2922-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011349790
187 https://doi.org/10.1007/s00280-015-2922-5
188 rdf:type schema:CreativeWork
189 sg:pub.10.1007/s00280-016-3218-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044012265
190 https://doi.org/10.1007/s00280-016-3218-0
191 rdf:type schema:CreativeWork
192 sg:pub.10.1038/35052073 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053565592
193 https://doi.org/10.1038/35052073
194 rdf:type schema:CreativeWork
195 sg:pub.10.1038/nrc2656 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035598015
196 https://doi.org/10.1038/nrc2656
197 rdf:type schema:CreativeWork
198 sg:pub.10.2165/00003088-199121040-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047951045
199 https://doi.org/10.2165/00003088-199121040-00002
200 rdf:type schema:CreativeWork
201 sg:pub.10.2165/00003088-199427040-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053348338
202 https://doi.org/10.2165/00003088-199427040-00002
203 rdf:type schema:CreativeWork
204 sg:pub.10.2165/11531280-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033453107
205 https://doi.org/10.2165/11531280-000000000-00000
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1016/s1470-2045(11)70336-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006777850
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1016/s1535-6108(02)00097-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009224253
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1056/nejmoa1113216 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013126608
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1056/nejmoa1703643 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085866538
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1093/annonc/mdt182 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049729330
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1097/cad.0000000000000016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030996000
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1158/0008-5472.can-08-4597 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053676255
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1196/annals.1430.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018747152
222 rdf:type schema:CreativeWork
223 https://doi.org/10.2174/138920012802138688 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069176119
224 rdf:type schema:CreativeWork
225 https://doi.org/10.4155/bio-2018-0196 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107648936
226 rdf:type schema:CreativeWork
227 https://www.grid.ac/institutes/grid.418119.4 schema:alternateName Institut Jules Bordet
228 schema:name Breast European Adjuvant Study Team (BrEAST) Data Center, Institut Jules Bordet, Boulevard de Waterloo 121 (7th Floor), 1000, Brussels, Belgium.
229 rdf:type schema:Organization
230 https://www.grid.ac/institutes/grid.418152.b schema:alternateName AstraZeneca (United States)
231 schema:name Executive Vice-President Research & Development Oncology, AstraZeneca, 950 Wind River Ln, Gaithersburg, MD, 20878, USA.
232 rdf:type schema:Organization
233 https://www.grid.ac/institutes/grid.418158.1 schema:alternateName Roche (United States)
234 schema:name Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA.
235 Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA. garg.amit@gene.com.
236 rdf:type schema:Organization
237 https://www.grid.ac/institutes/grid.419166.d schema:alternateName Instituto Nacional do Câncer
238 schema:name Instituto Nacional de Câncer, Praça Cruz Vermelha, 23-Centro, Rio de Janeiro, 20230-130, Brazil.
239 rdf:type schema:Organization
240 https://www.grid.ac/institutes/grid.419227.b schema:alternateName Roche (United Kingdom)
241 schema:name Roche Products Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, UK.
242 rdf:type schema:Organization
243 https://www.grid.ac/institutes/grid.427828.3 schema:alternateName Breast International Group
244 schema:name Breast International Group, Boulevard de Waterloo 76, 1000, Brussels, Belgium.
245 rdf:type schema:Organization
246 https://www.grid.ac/institutes/grid.434440.3 schema:alternateName German Breast group
247 schema:name German Breast Group, GBG Forschungs, Martin-Behaim-Str. 12, 63263, Neu-Isenburg, Germany.
248 rdf:type schema:Organization
249 https://www.grid.ac/institutes/grid.443984.6 schema:alternateName St James's University Hospital
250 schema:name University of Leeds and Leeds Teaching Hospitals Trust, St James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK.
251 rdf:type schema:Organization
252 https://www.grid.ac/institutes/grid.4861.b schema:alternateName University of Liège
253 schema:name International Breast Cancer Study Group, CHU Liège and Liège University, Domaine Universitaire du Sart Tilman, B35, 4000, Liège, Belgium.
254 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...